Lamotte Mark, Annemans Lieven, Bridgewater Ben, Kendall Simon, Siebert Markus
IMS Health Economics and Outcomes Research, Brussels, Belgium.
Eur J Cardiothorac Surg. 2007 Nov;32(5):702-10. doi: 10.1016/j.ejcts.2007.07.027. Epub 2007 Sep 4.
Current drug treatment for atrial fibrillation is suboptimal and percutaneous catheter-based ablation techniques may be associated with complications. The aim of this study is to assess the cost-effectiveness of (1) high-intensity focused ultrasound (HIFU)-assisted surgical ablation, (2) the classic 'cut and sew' maze procedure and (3) percutaneous ablation, all concomitant to cardiac surgery (e.g. CABG, valve repair) in comparison with non-interventional (drug) treatment.
A Markov model was developed to predict the cost-effectiveness of the interventional approaches. The model consisted of four disease states (sinus rhythm without complications, atrial fibrillation without complications, stroke and death), allowing for 3-monthly transitions between these states and using direct UK costs from the National Health Service perspective. Clinical input data are obtained from literature and cost input data from National Health Service sources and literature. Five-year total and incremental costs are calculated. Incremental effects are expressed in quality-adjusted-life-years-gained (QALYG).
All interventional treatments show good incremental cost-effectiveness ratios in all atrial fibrillation types, compared to drug treatment. For classic maze the incremental cost-effectiveness ratio compared to non-interventional atrial fibrillation treatment varies from 1343 to 3471 GBP/QALYG, for HIFU-assisted surgical ablation from 4005 to 7448 GBP/QALYG and for percutaneous ablation from 7041 to 17,372 GBP/QALYG depending on the atrial fibrillation type. Sensitivity analyses showed the robustness of the data.
Performing a classic maze procedure or HIFU-assisted surgical ablation concomitant to a scheduled CABG or valve procedure is highly cost-effective. Performing a percutaneous ablation in a subsequent procedure is also cost-effective, but to a lower extent. Both the maze procedure and the HIFU-assisted surgical ablation are cheaper and more effective than percutaneous ablation in a subsequent procedure.
目前用于治疗心房颤动的药物疗效欠佳,基于经皮导管的消融技术可能会引发并发症。本研究旨在评估与非介入性(药物)治疗相比,(1)高强度聚焦超声(HIFU)辅助手术消融、(2)经典“切割缝合”迷宫手术和(3)经皮消融(均与心脏手术如冠状动脉旁路移植术、瓣膜修复术同时进行)的成本效益。
构建马尔可夫模型以预测介入治疗方法的成本效益。该模型包含四种疾病状态(无并发症的窦性心律、无并发症的心房颤动、中风和死亡),允许这些状态之间每3个月进行一次转换,并从英国国家医疗服务体系的角度使用直接成本。临床输入数据来自文献,成本输入数据来自国家医疗服务体系来源和文献。计算五年的总成本和增量成本。增量效果以获得的质量调整生命年(QALYG)表示。
与药物治疗相比,所有介入治疗在各类心房颤动中均显示出良好的增量成本效益比。对于经典迷宫手术,与非介入性心房颤动治疗相比,增量成本效益比在1343至3471英镑/QALYG之间;对于HIFU辅助手术消融,在4005至7448英镑/QALYG之间;对于经皮消融,在7041至17372英镑/QALYG之间,具体取决于心房颤动类型。敏感性分析表明数据具有稳健性。
在计划进行的冠状动脉旁路移植术或瓣膜手术同时进行经典迷宫手术或HIFU辅助手术消融具有很高的成本效益。在后续手术中进行经皮消融也具有成本效益,但程度较低。迷宫手术和HIFU辅助手术消融在后续手术中都比经皮消融更便宜且更有效。